After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for 10x Genomics Inc. (TXG) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$1.83, or -5.72%, to $30.15. Volume reached 37,002 shares, with price reaching a high of $30.23 and a low of $30. Most recently, Yahoo Finance reported about the stock as it publicized that 10x Genomics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference.
TXG belongs to the Healthcare sector of the NASDAQ while operating in the Health Information Services industry. At the end of the last regular session, the stock closed at $30.23 and fluctuated between $32.79 as its day high and $30.23 as its day low. The current market capitalization of 10x Genomics Inc. is $3.76B. A total of 1.14 million shares were traded on the day, compared to an average of 1.42M shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, TXG has seen 0 BUY and 3 SELL insider trades, representing the acquisition of 0 and the disposition of 4,994 shares. Over the last 12 months, there were 42 BUYs and 146 SELLs from insiders. Insiders purchased 684,379 shares during that period but sold 409,654.
In the most recent transaction, McAnear Justin J. sold 987 shares of TXG for 35.19 per share on Aug 23. After the transaction, the Chief Financial Officer now owns 58,092 company shares. In a previous transaction on Aug 23, Saxonov Serge sold 2,715 shares at 35.19 per share. TXG shares that Chief Executive Officer owns now total 966,102.
Among the insiders who sold shares, Hindson Benjamin J. disposed of 1,292 shares on Aug 23 at a per-share price of $35.19. This resulted in the holding 186,246 shares of TXG after the transaction. In another insider transaction, Saxonov Serge sold 2,656 shares at $48.76 per share on May 23. Company shares held by the Chief Executive Officer now total 968,817.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for TXG in the last 3 months, the mean price target is $55.63 with high estimates of $70.00 and low estimates of $35.00. In terms of 52-week highs and lows, TXG has a high of $187.85 and a low of $29.17.
As of this writing, TXG has an earnings estimate of $-0.46 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of $-0.38 per share and a lower estimate of $-0.61. The company reported an EPS of $-0.57 in the last quarter, which was -42.5% lower than expectations of $-0.4.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 10 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for TXG is Hold with a score of 3.75. A total of 6 analysts rated the stock as Buy while 1 rated it as Overweight while 1 rated it as Hold. Among the other participants, 1 thought the stock was Underweight and 1 thought it should be Sold.